Business Wire

TOURISE Destination Initiative Calls for Global Action for Urban Tourism Safety Through AI

13.11.2025 15:42:00 CET | Business Wire | Press Release

Share

Launched today at the TOURISE Summit, the TOURISE Destination Initiative (TDI) brings together global leaders from government, international organizations, academia, and the private sector, to transform destinations into living laboratories for tourism innovation. Guided by its Declaration of Principles, TDI champions safety, environmental stewardship, cultural preservation, and community-centered development through responsible technology and multi-sector collaboration.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113796086/en/

His Excellency Ahmed Al Khateeb, Saudi Arabia's Minister of Tourism and Chairman of TOURISE, launches the TOURISE Destination Initiative, a global coalition to shape the future of tourism through a destination-centric approach, with co-chairs H.R.H. Prince Turki bin Talal bin Abdulaziz Al Saud, Governor of Aseer Province, and Luigi Brugnaro, Mayor of Venice. They are joined with the TDI founding members and mayors

TDI is co-chaired by Prince Turki bin Talal bin Abdulaziz Al Saud, Governor of Aseer Province, and Luigi Brugnaro, Mayor of Venice, and founding members include:

  • Patricia de Lille, Minister of Tourism, Republic of South Africa
  • Mateo Julián Estrella Durán, Minister of Tourism, Republic of Ecuador
  • Thoriq Ibrahim, Minister of Tourism, Republic of Maldives
  • Francis Suarez, Mayor of Miami, United States
  • Mohamed Sefiani, Mayor of Chefchaouen, Morocco
  • Natalia Bayona, Executive Director, UN Tourism
  • Arnaud Ngatcha, Deputy Mayor of Paris
  • Iván Azurdia, Director of Tourism Development, Guatemala Institute of Tourism
  • Jordan Tan, Chief Technology Officer & Chief Data Officer, Singapore Tourism Board
  • Jon Berroya, Director, Government Affairs & Public Policy, Google
  • Mauricio Rodas, Visiting Scholar, University of Pennsylavnia
  • Matthijs Bouw, Founder, One Architecture and Urbanism

TDI’s first project, “AI for Tourism Safety,” aims to promote the responsible deployment of AI in TDI member destinations. The project builds on insights from Surveillance or Safety? How Cities are Rewriting Tourism, a white paper by the University of Pennsylvania’s Penn Institute for Urban Research (Penn IUR). Authored by Mauricio Rodas—Visiting Scholar at Penn IUR and former Mayor of Quito—the paper explores the ethical and operational challenges of AI in urban tourism and was launched alongside TDI.

“As destinations, we carry the responsibility of protecting what makes us unique, our people, our heritage, and our future,” said His Royal Highness Prince Turki bin Talal bin Abdulaziz Al Saud, Governor of Aseer Province and Co-Chair of the TOURISE Destination Initiative. “Through TDI, we are creating a shared space for cities to lead; by embracing innovation rooted in ethics and empathy, we ensure that tourism becomes a force for safety, dignity, and sustainable development.”

“Urban destinations are the heartbeat of the global tourism industry, and it is imperative that no city, anywhere in the world, ever feels unsafe for its visitors or residents,” said His Excellency Ahmed Al-Khateeb, Minister of Tourism and Chairman of TOURISE. “With the TOURISE Destination Initiative, we are calling on cities to lead with integrity. Safety innovations must be anchored in responsible governance. By applying technology with foresight, we protect travelers and reinforce the trust that defines the future of tourism.”

As cities face rising crime, digital threats, and traveler anxiety, TDI will guide the ethical adoption of AI to enhance safety while establishing new benchmarks for transparency and trust.

Mauricio Rodas added, “Although nine out of ten mayors express interest in integrating artificial intelligence into city management, only 2 percent of cities are actively deploying it for safety, mainly due to a lack of policy and regulatory frameworks. TDI’s AI for Tourism Safety project is designed to close that gap by offering practical guidance for cities to protect everyone who calls a destination home, whether permanently or temporarily.”

About TOURISE

TOURISE is the world’s premier platform shaping a new horizon for global tourism.

Under the umbrella of the Saudi Ministry of Tourism, powered by the Saudi Tourism Authority, the inaugural TOURISE Summit will take place November 11–13, 2025, in Riyadh, Saudi Arabia.

The event will convene visionaries from government, business, investment, tourism, and technology to drive transformative deals and deliver high-impact initiatives that redefine the future of the global tourism industry.

TOURISE ensures worldwide participation while offering access to decision-makers shaping the industry’s evolution. Following the Summit, TOURISE will continue as a year-round platform where bold ideas turn into real-world solutions.

This is where the next 50 years of tourism are shaped. Together, we are unstoppable.

For more information visit www.tourise.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20251113796086/en/

Contacts

For media inquiries, please contact Media@TOURISE.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye